Baseline Workup and Monitoring for Hidradenitis Suppurativa Patients Starting Adalimumab
Before initiating adalimumab for hidradenitis suppurativa, you must screen for tuberculosis (TB) and hepatitis B/C, and establish baseline inflammatory markers including CBC with differential and CRP. 1
Pre-Treatment Screening Requirements
Mandatory Infectious Disease Screening
Tuberculosis screening is required before starting adalimumab and can be performed with tuberculin skin test (TST) and/or interferon-gamma release assay (IGRA). In endemic regions with high BCG vaccination rates, IGRA may provide better sensitivity and specificity 1.
- For latent TB not at high risk: Start prophylactic antibiotics at least 1 month before adalimumab initiation 1
- For latent TB at high risk or from endemic areas: Complete prophylactic antibiotics before starting adalimumab 1
- Preferred TB treatment regimen: 4-month course of oral rifampin 1
Hepatitis B and C screening is mandatory before starting immunosuppressants or biologics 1. This includes:
- Hepatitis B surface antigen (HBsAg)
- Hepatitis B core antibody
- Hepatitis C antibody
Baseline Laboratory Assessment
Obtain the following baseline labs:
- Complete blood count (CBC) with differential - to calculate neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) 2, 3
- C-reactive protein (CRP) - baseline inflammatory marker 2, 3, 4
- Erythrocyte sedimentation rate (ESR) - alternative inflammatory marker less affected by obesity 3
These inflammatory markers (NLR, PLR, MLR, CRP) correlate with disease severity and show significant reduction with adalimumab treatment, potentially predicting treatment response 2.
Clinical Assessment at Baseline
Document the following clinical parameters:
- International Hidradenitis Suppurativa Severity Score System (IHS4) - count of inflammatory nodules, abscesses, and draining tunnels
- Dermatology Life Quality Index (DLQI) - quality of life assessment
- Pain Visual Analog Scale (PI-NRS) - pain severity scoring 4
- Hurley stage - disease severity classification 4
- Affected anatomical sites - axilla, buttocks, inguinal/femoral regions 4
Ongoing Monitoring During Treatment
Laboratory Monitoring Schedule
At 12-16 weeks post-initiation:
- Repeat CBC with differential (NLR, PLR, MLR)
- Repeat CRP
- These markers show significant reduction by week 12-16 in responders 2, 4
Annual TB screening is recommended if the patient requires glucocorticoids exceeding 15 mg prednisone equivalent daily for at least 4 weeks 1.
Clinical Response Assessment
Primary endpoint at 12 weeks: Hidradenitis Suppurativa Clinical Response (HiSCR) - defined as ≥50% reduction in inflammatory nodule and abscess count with no increase in draining tunnels 5
Week 12 response rates from PIONEER trials: 42-59% achieve HiSCR versus 26-28% with placebo 5
Monitor at weeks 12,24, and 36:
- IHS4 score
- DLQI score
- Pain VAS score
- Clinical examination of lesions
Therapeutic Drug Monitoring (TDM)
For patients with suboptimal response, consider therapeutic drug monitoring:
- Target adalimumab trough level: ≥10.6-10.7 μg/mL for optimal response 6, 7
- Timing: After ≥4 weeks of therapy to ensure steady state 6
- Anti-adalimumab antibody testing: Indicated if subtherapeutic levels detected 7
In patients with suboptimal response on standard dosing (40 mg weekly), approximately 37% have subtherapeutic drug levels, with only 21% having anti-adalimumab antibodies 7. This identifies candidates for dose escalation rather than switching therapy.
Important Clinical Considerations
Nearly 40% of week 12 non-responders achieve response by week 36 with continued treatment 5, so premature discontinuation should be avoided. Conversely, approximately half of week 12 responders lose response by week 36 despite weekly maintenance dosing 5.
Concomitant tetracycline-class antibiotics can be continued during adalimumab therapy and were used in 19% of PIONEER 2 trial participants 5.
Obesity and metabolic syndrome are common comorbidities that can confound CRP interpretation 3. ESR may be less affected by these confounders but requires further validation 3.